1172PA first-in-class, first-in-human phase I/IIa trial of CAN04, targeting interleukin-1 receptor accessory protein (IL1RAP), in patients with solid tumors. (23rd October 2018) - Awada, A; Eskens, F A L M; Robbrecht, D G; Lassen, U N; Sorensen, M; Schellens, J H M; de Groot, J S; Jungels, C; Aftimos, P G; Fretland, S O; Thorsson, L; Guren, T K